Analyst firms · Morgan Stanley · BLCO
Morgan Stanley BLCO price target and rating history
Bausch + Lomb Corporation (BLCO) · Health Care
Morgan Stanley rates Bausch + Lomb Corporation (BLCO) Overweight with a $21 price target, as of its latest action on Dec 2, 2025. It has published 4 rating actions on BLCO since May 2023, including 2 upgrades and 1 downgrade. Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. Morgan Stanley's target matches it.
- Current rating
- Overweight
- Price target
- $21
- Median target, all firms
- $21
- Actions on BLCO
- 4
Morgan Stanley price target on BLCO
Every Morgan Stanley rating on BLCO
- Dec 2, 2025
- Dec 2, 2024
- May 6, 2024
- May 30, 2023
How other firms rate BLCO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | $22 | Nov 2, 2026 |
| Barclays | Overweight | $24 | Oct 7, 2026 |
| Leerink Partners | Outperform | $24 | Sep 9, 2026 |
| UBS | Buy | $21 | Jul 28, 2026 |
| Evercore ISI | In-line | $18 | Jan 5, 2026 |
| Citigroup | Buy | $20 | Dec 11, 2025 |
| Morgan Stanley | Overweight | $21 | Dec 2, 2025 |
Questions about Morgan Stanley and BLCO
- What is Morgan Stanley's price target for BLCO?
- Morgan Stanley's latest stated price target for Bausch + Lomb Corporation (BLCO) is $21, from its action on Dec 2, 2025.
- What is Morgan Stanley's rating on BLCO?
- Morgan Stanley rates BLCO Overweight, a bullish rating, as of Dec 2, 2025.
- When did Morgan Stanley last change its view on BLCO?
- On Dec 2, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $21.
- How does Morgan Stanley's BLCO target compare with other analysts?
- Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. Morgan Stanley's target matches it.
More BLCO rating histories
All Morgan Stanley ratingsBLCO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.